Cell competition and selection as a driver of malignant progression

by Alexey Bersenev on July 9, 2011 · 1 comment

in cancer, niche

Guys, we’re experiencing the era of tumor environment appreciation in cancer research. Cancer progression is not cell autonomous! It depends so much on the environmental context. But to complete a picture, please take into account a competition between cancer and normal cells for their environment.

Cell competition as a biological phenomenon has been studied for the last 30 years. But only recently in mammals and very recently in stem cell biology. I’ll try briefly to summarize the role of cell competition in cancer progression, including stem cell.

What cells could compete with each other?

  1. Normal cells could compete for organ integrity in development and normal tissue turnover
  2. Normal stem cells could compete with each other for occupancy of the niche
  3. Finally, cancer cells could compete with normal cells for environment in order to progress

Cell competition in normal conditions
Cell competition for the first time was discovered in Drosophila:

Cell competition, a well-recognized phenomenon of cell-cell interaction, was first discovered in Drosophila wing imaginal discs, where growth-disadvantageous cells are eliminated by wild-type cells, which subsequently undergo compensatory proliferation to maintain proper disc size.

What is the biological meaning of cell competition in the normal organism?
Imagine this: on the planet Earth (multicellular organism) people (cells) live in cities or communities (tissues), forming more complex structures – countries (organs). Because members of these communities could be socially unequal, they need some sort of control (law) or “moral principles” if you will, in order to maintain integrity. This is a principle of cell competition in normal multicellular organism, guys.

Cell competition as a mechanism to maximize tissue fitness:

Cell-autonomous apoptosis is enough to kill cells that have major functional problems. However, if the cell that the multicellular animal wants to get rid of is viable, another discriminatory step is required to identify such suboptimal cells. The fact that all initial examples of cell competition resulted in wild-type cells being the winners led to the proposal that cell competition may be an efficient mechanism to maximize tissue fitness and optimize organ function, ensuring that viable but suboptimal cells do not accumulate during development or ageing.

So, cell competition seem to be responsible for maintainance of tissue integrity in a multicellular organism. One more important definition – cell fitness:

… “fitness” is a measure of the ability of a cell of a certain genotype to pass this genotype to subsequent cell generations, as governed by competition for similar niches.

Cell competition in malignant progression – lessons from Drosophila
Cell competition in cancer progression could occur on different levels:

  1. cancer non-stem cell versus normal cells
  2. cancer stem cells versus normal stem cells

Competition between cancer cells and normal cells was described very well in Drosophila:

What if a transformed cell could proliferate without producing morphological malformations, because the increase in cell number was balanced by the apoptotic elimination of surrounding cells and, therefore, the total cell number did not change? An intriguing phenomenon in D. melanogaster known as ‘cell competition’ has been described to do just this: cells proliferate by killing surrounding wild-type cells by apoptosis so that the total cell number does not change. As a consequence, clonal expansion did not generate morphological aberrations and the growth of these cells passed unnoticed.

At least two types of mutations, which can trigger cell competition in cancer development, were identified in Drosophilad-Myc and Hippo pathway:

A two- fold increase in DMYC levels is enough to transform cells into super-competitors

As Myc family genes are prominently involved in human cancers and there is increasing evidence that Hippo pathway components are deregulated in human tumours, super-competition has been hypothesized to be involved in the early stages of cancer formation.

I’d like to point out two very Interesting biological phenomena associate with cancer cell competition described in drosophila that are nicely summarized in this review:

  1. Clonal expansion upon competition required killing of neighbouring cells. Therefore cancer cell competition is very early event of malignant development and due to initial absence of tissue growth could be undetectable. So, apoptosis could have a dual role in carcinogenesis: (i) inhibition to promote self-survival and proliferation and (ii) killing of surrounding competitors.
  2. On one hand, overexpression of some genes could transform cells into super-competitors, leading to malignant progression (d-Myc, Hippo pathway). But, on the other hand, overexpression of such gene as Minute, involved in cell competition, can not drive competition above normal levels.

Stem cell competition for niche occupancy
Despite very nice work on Drosophila, we still don’t know how cell competition occurs in mammals. But there are some evidence that cell competition in adult mammals occurs on the level of somatic (tissue) stem cells and their niches. Natural (Darwinian) selection and phenotypic evolution through competition of stem cell for the niche was nicely modeled by Marc Mangel in 2008:

… in healthy organisms, we should not expect the stem populations to be at their maximum sizes.

To understand fully how natural selection acts on a stem cell, we need to consider the fitness of a focal stem cell. Stem cells (and transit amplifying cells) do not by themselves achieve fitness. Rather, they support the organism – which can be viewed as an organized collection of fully differentiated cells. Fitness of the focal stem cell depends upon what it does, what the other stem cells in the niche do, and how many transit amplifying and differentiated cells are present.

Hematopoietic stem cells (HSC) re-circulate and compete for their niches in normal steady-state conditions as well as in bone marrow transplantation settings. In order to assess HSC fitness and competition, bone marrow transplant should be done:

… marrow engraftment is determined by stem cell competition indicates that final donor chimerism after transplant is directly related to the ratio of donor to residual host stem cells.

Leukemic stem cell competition for bone marrow niches
Competitive repopulation assay in experimental bone marrow transplantation allows to identify gene-candidates or mutations associated with high (cells-winners) or low (cells-losers) or super-high (cells-cheaters) stem cell fitness. Loss of tumor-suppressor genes, such as p53, in competitive settings could generate HSC-winners and cheaters. Later it could lead to clonal selection, expansion and leukemogenesis. Interestingly, unlike Drosophila, HSC-losers undergo senescence, but do not get killed by winners via apoptosis:

We propose that p53-mediated stem cell-specific, senescence-like response to DNA damage operates as a “memory of past damage”: while still compatible with proliferation, it permanently marks HSPCs that have experienced DNA damage and thus promotes their gradual replacement by undamaged cells over time, if such cells are available.

In my recent post about Bondar-Medzhitov study , I noted:

… most importantly, this work provided evidence for carcinogenesis (irradiation)- induced selection. It contradicts the assumption that oncogenic mutation alone caused by carcinogenic factor can initiate the malignant process (mutagenesis versus selection). It is also important that this selection occurs in context of stem cell niche and can give us a clue of how neoplastic process is initiated and progresses.

Not only loss of p53, but such oncogenic mutations as Bcr-Abl can give competitive advantage to hematopoietic progenitor cells and cause age-associated leukemogenesis:

… Bcr-Abl provides a much greater competitive advantage to old B-lymphoid progenitors compared with young progenitors, coinciding with restored kinase signaling pathways, and that this enhanced competitive advantage translates into increased promotion of Bcr-Abl-driven leukemias. Moreover, impairing IL-7-mediated signaling is sufficient to promote selection for Bcr-Abl-expressing B progenitors. These studies support an unappreciated causative link between aging and cancer: increased selection of oncogenic mutations as a result of age-dependent alterations of the fitness landscape.

This is actually the first study which demonstrates competition of progenitor cells (B-cell progenitor) for environment (IL-7 signaling) in context of aging. Interestingly, young normal hematopoietic progenitors beat co-transplanted Bcr-Abl-expressing cells in competition for rescue of IL-7 signaling and normal B-cell lymphopoiesis.

The role of malignant cell competition in bone marrow niches was elucidated in some human hematological malignancies.

Cancer cell competition driven by malignant niches
In the model of B-ALL, leukemic cells were able to modify normal HSC niches in bone marrow, created malignant niches. Created leukemic niches outcompete native HSC niches, but were not able to maintain normal hematopoiesis. This is the only study, proposed so-called “niche competition” for stem cell engagement in leukemia model:

We have shown that leukemic proliferation in the BM alters the stromal microenvironment and creates malignant niches that outcompete native HPC niches for CD34+ cell engraftment. Normal CD34+ cells engaged by the malignant niche exhibit abnormal behavior.

Our results raise many questions about the nature of tumor-host interactions: Do leukemic cells reorganize the molecular microenvironment specifically to entrap HPCs, or is the creation of competitive HPC niches a coincidental side effect of leukemic growth?

Cancer clonal selection driven by competition
The mathematical model of cancer progression indicates that, harsh survival conditions, provided by malignant niches, could drive evolution of selected malignant clones and cancer progression. So, not just mutations per se, but triggering of cell competition by environmental changes will cause early “malignant onset”. Selection of the fitter cancer cell clone, as a consequence of competition, will drive further malignant progression:

…mild microenvironment conditions (e.g., normoxia, homogeneous matrix) allow clones with similar aggressive traits to coexist with less aggressive phenotypes in a heterogeneous tumor mass with smooth, noninvasive margins. Thus, the genetic make-up of a cancer cell may realize its invasive potential through a clonal evolution process driven by definable microenvironmental selective forces.

Recent study demonstrates that interaction of embryonic epithelial cell remnants with surrounding tissues could trigger Barrett’s like metaplasia:

Our findings suggest that certain precancerous lesions, such as Barrett’s, initiate not from genetic alterations but from competitive interactions between cell lineages driven by opportunity.

Concluding remark:
The possible causes of cell competition, leading to malignant progression:

  1. Oncogenic mutations, transforming normal cells into “super-competitors”;
  2. Loss of fitness by normal cells due to aging (aged hematopoietic stem cells and lymphoid progenors) or external insults (irradiation);
  3. Appearance of aberrant niches with abnormal environment, in which only abnormal (malignant) cells could engraft, survive and proliferate.

Finally, guys, please maintain your stem cell fitness! Start to think about it while you’re young. Take your butt off the chair and go exercise!

{ 1 comment… read it below or add one }

Lorraine Meisner July 12, 2011 at 12:33 am

I completely agree with you. A cell with mutations capable of causing cancer cannot expand when surrounded with an overwhelming number of normal cells. Exposures or age associated decreases in the number of competing normal cells facilitates expansion of premalignant cells, which can undergo further mutations to become more aggressive, which is why most cancers occur in older persons or those with mutagenic exposures. Cancer in younger individuals requires more mutations to compete within a niche densely populated with normal cells, which is why the same type of cancer (such as breast ca) tends to be more advanced and treatment resistant in young women.


Leave a Comment

Previous post:

Next post: